Earnings ·
Immuron Limited reported preliminary results for the fiscal year ended June 30, 2026, with revenue increasing 5.9% to…
IMRNImmuron Ltd
Immuron Limited reported preliminary results for the fiscal year ended June 30, 2026, with revenue increasing 5.9% to A$7.7 million and net loss narrowing by 26.4% to A$3.8 million. Cash reserves rose significantly to A$9.0 million from A$2.8 million the prior year, supported by a large equity raise via an At-the-Market facility that increased share count to over 322 million. The company achieved key clinical milestones, including FDA approval of its IND for IMM-529 and completion of the IMM-124E trial, while signing a U.S. Department of Defense research agreement. Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for infectious diseases.